Literature DB >> 15389589

Alpha-interferon and its effects on signal transduction pathways.

Michele Caraglia1, Monica Marra, Girolamo Pelaia, Rosario Maselli, Mario Caputi, Serafino A Marsico, Alberto Abbruzzese.   

Abstract

Interferon-alpha (IFNalpha) is a recombinant protein widely used in the therapy of several neoplasms such as myeloma, renal cell carcinoma, epidermoid cervical and head and neck tumors, and melanoma. IFNalpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. However, the way by which tumor cell growth is directly suppressed by IFNalpha is not well known. Wide evidence exists on the possibility that cancer cells undergo apoptosis after the exposure to the cytokine. Here we will review the consolidate signal transducer and activator of transcription (STAT)-dependent mechanism of action of IFNalpha. We will discuss data obtained by us and others on the triggering of the stress-dependent kinase pathway induced by IFNalpha and its correlations with the apoptotic process. The regulation of the expression of proteins involved in apoptosis occurrence will be also described. In this regard, IFNalpha is emerging as a post-translational controller of the intracellular levels of the apoptosis-related protein tissue transglutaminase (tTG). This new way of regulation of tTG occurs through the modulation of their proteasome-dependent degradation induced by the cytokine. Until today, inconsistent data have been obtained regarding the clinical effectiveness of IFNalpha in the therapy of solid tumors. In fact, the benefit of IFNalpha treatment is limited to some neoplasms while others are completely or partially resistant. The mechanisms of tumor resistance to IFNalpha have been studied in vitro. The alteration of JAK-STAT components of the IFNalpha-induced signaling, can be indeed a mechanism of resistance to IFN. However, we have recently described a reactive mechanism of protection of tumor cells from the apoptosis induced by IFNalpha dependent on the epidermal growth factor (EGF)-mediated Ras/extracellular signal regulated kinase (Erk) signaling. The involvement of the Ras-->Erk pathway in the protection of tumor cells from the apoptosis induced by IFNalpha is further demonstrated by both Ras inactivation by RASN17 transfection and mitogen extracellular signal regulated kinase 1 (Mek-1) inhibition by exposure to PD098059. These data strongly suggest that the specific disruption of the latter could be a useful approach to potentiate the antitumour activity of IFNalpha against human tumors based on the new mechanistic insights achieved in the last years. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389589     DOI: 10.1002/jcp.20137

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  24 in total

1.  A novel type II membrane receptor up-regulated by IFN-alpha in fibroblasts functions in cell proliferation through the JAK-STAT signalling pathway.

Authors:  L-D Liu; C-H Dong; H-J Shi; H-L Zhao; L-C Wang; S-H Ma; Q-H Li
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

2.  The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways.

Authors:  Jonathan M Hernandez; Abul Elahi; Whalen Clark; Leigh Ann Humphries; Jian Wang; Alex Achille; Ed Seto; David Shibata
Journal:  DNA Cell Biol       Date:  2015-05-19       Impact factor: 3.311

3.  Citrinin induces apoptosis via a mitochondria-dependent pathway and inhibition of survival signals in embryonic stem cells, and causes developmental injury in blastocysts.

Authors:  Wen-Hsiung Chan
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

4.  Gene expression profiling in Salmonella Choleraesuis-infected porcine lung using a long oligonucleotide microarray.

Authors:  Shu-Hong Zhao; Daniel Kuhar; Joan K Lunney; Harry Dawson; Catherine Guidry; Jolita J Uthe; Shawn M D Bearson; Justin Recknor; Dan Nettleton; Christopher K Tuggle
Journal:  Mamm Genome       Date:  2006-07-15       Impact factor: 2.957

5.  Serum angiogenin levels predict treatment response in patients with stage IV melanoma.

Authors:  Pia Vihinen; Minna Kallioinen; Meri-Sisko Vuoristo; Johanna Ivaska; Kari J Syrjänen; Marjo Hahka-Kemppinen; Pirkko-Liisa Kellokumpu-Lehtinen; Seppo O Pyrhönen
Journal:  Clin Exp Metastasis       Date:  2007-08-29       Impact factor: 5.150

6.  Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.

Authors:  Feyza Gunduz; Chaithanya Mallikarjun; Luis A Balart; Srikanta Dash
Journal:  Exp Mol Pathol       Date:  2013-11-08       Impact factor: 3.362

7.  Inflammation activates the interferon signaling pathways in taste bud cells.

Authors:  Hong Wang; Minliang Zhou; Joseph Brand; Liquan Huang
Journal:  J Neurosci       Date:  2007-10-03       Impact factor: 6.167

8.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Authors:  Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

9.  Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells.

Authors:  Fang Hu; Thaddeus W W Pace; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2009-01-08       Impact factor: 7.217

10.  Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization.

Authors:  Arezou A Ghazani; Nona Arneson; Keisha Warren; Melania Pintilie; Jane Bayani; Jeremy A Squire; Susan J Done
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.